Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC add-on to ICS/LABA in COPD
NL-OMON41117Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoints: Trough FEV1 on day 85 and Incidence of adverse events. Started Sep 2014; status: active, not recruiting.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON41117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41117.